The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD). David Singh, Eric D. Bateman, Paul W. Jones. The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease. Eric D. Bateman, David Singh, Paul W. Jones, Alvar. This paper presents results from a phase III study of longer duration (Aclidinium To Treat Airway obstruction In COPD patieNts; ATTAIN), which.
|Country:||Bosnia & Herzegovina|
|Published (Last):||14 October 2007|
|PDF File Size:||18.61 Mb|
|ePub File Size:||3.89 Mb|
|Price:||Free* [*Free Regsitration Required]|
Int J Clin Pharmacol Ther. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
Safety and tolerability of aclidinium bromide in patients with COPD: Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.
Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary acludinium, in healthy participants. Three long-acting muscarinic antagonists LAMAs are now available in Europe, providing clinicians and patients with a choice of aclidimium, which is important in COPD, which is clinically a heterogeneous disease.
Tiotropium has been widely used over axlidinium last decade as once-daily maintenance therapy in stable COPD. Phase II Chanez et al European Medicines Agency; Pharmacologic and pharmacokinetic profile Preclinical studies have shown that aclidinium displays high affinity for all five muscarinic receptors, with kinetic selectivity for M 3 receptors over M 2and a shorter duration of action and a faster onset compared with tiotropium bromide.
Furthermore, a higher proportion of patients attsin with aclidinium achieved the MCID in each of these measures, compared with placebo.
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Global Initiative for Chronic Obstructive Lung Disease [webpage on the Internet] Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [updated Jan ] [Accessed November 12, attajn.
Data reported as least squares mean standard error. Support Center Support Center.
COPD Efficacy Study | TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder)
Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Aclidinium bromide for stable chronic obstructive pulmonary disease. Published online Mar The author and his institution have received consulting and lecture fees from Almirall S. It has been extensively studied in patients with COPD — a recent Cochrane review identified 22 studies of good methodological quality that aclidiium enrolled 23, participants with COPD.
Pharmacokinetic studies in healthy volunteers showed that it is poorly absorbed into plasma and rapidly hydrolyzed into two major inactive metabolites, resulting in limited systemic exposure.
In the ACCORD COPD I study, 31 night-time and morning COPD symptoms were all significantly reduced among patients treated with aclidinium compared with those who received placebo Figure 5and the impact of breathlessness on early morning activities was also significantly reduced with aclidinium versus placebo Figure 6. Open in a separate window. Subsequently, studies investigating higher doses and alternative dosing regimens were conducted, 2930 leading to two Phase III studies: Food and Drug Administration Tudorza Pressair: Significant improvements sstudy seen in breathlessness, health status, and COPD symptoms in the pivotal trials.
This showed that aclidinium improved the total score wtudy the component scores breathlessness, chest symptoms, and cough and sputum significantly more than placebo Figure 7.
Reproduced with permission of the European Respiratory Society: Reduced COPD exacerbations associated with aclidinium bromide versus placebo: Expert Opin Drug Deliv. Breathlessness, health status, and COPD symptoms with aclidinium Significant improvements were seen in breathlessness, health status, and COPD symptoms in the pivotal trials.
Preclinical and pharmacological studies demonstrating low systemic bioavailability and a low propensity to induce cardiac arrhythmias were translated into a favorable tolerability profile in the clinical trial program — the adverse event profile of aclidinium was similar to placebo, with a low incidence of anticholinergic and cardiac adverse events.
Well tolerated, no anticholinergic side effects reported, no clinical effect on EKG parameters. N Engl J Med.
Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
This article has been cited by other articles in PMC. Eur Respir JOctober While additional studies are needed to evaluate its full clinical potential, aclidinium is an important part of this recent expansion of LAMA therapeutic options, providing clinicians and patients with an effective and well-tolerated COPD treatment. Mean area under the FEV 1 curve 0—24 h time interval was 1. Study acronym and reference Study treatments N Duration weeks Key efficacy results treated vs placebo, respectively: Discussion As noted in the current GOLD guidelines, tiotropium, aclidinium, and glycopyrronium can all be considered as appropriate options for maintenance treatment in the stable COPD patient.
The safety profile of aclidinium was comparable to placebo. Reproduced with permission of Informa Healthcare.